Posted by Michael Wonder on 06 Dec 2021
PHARMAC negotiates deal with Pfizer for its promising new oral antiviral treatment for COVID-19
6 December 2021 - PHARMAC has negotiated an agreement with Pfizer for its promising new oral anti-viral treatment to treat COVID-19.
“Getting vaccinated is the best defence against COVID-19. We are pleased that we have secured an additional treatment to help those who become unwell,” says PHARMAC’s Chief Executive Sarah Fitt. “The signed agreement is for supply of 60,000 courses, giving Kiwis another line of defence against the virus.”
